Free radical production in ischemic cerebrovascular disease

Japanese Journal of Geriatrics

Volumn 40, Issue 4, 2003, Pages 319-321

  Takizawa, Shunya ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; FREE RADICAL; SCAVENGER;

ARTICLE; BRAIN INFARCTION; DRUG COMBINATION; HUMAN; METABOLISM; REPERFUSION;

CEREBRAL INFARCTION; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; REPERFUSION;

EID: 0042383429     PISSN: 03009173     EISSN: None     Source Type: Journal    
DOI: 10.3143/geriatrics.40.319     Document Type: Article

References (15)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995: 333: 1581-1587.
2. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. JAMA 1999: 282: 2019-2026.
3. Dawson TM, Dawson VL, Snyder SH: A novel neuronal messenger molecule in brain: The free radical, nitric oxide. Ann Neurol 1992 ; 32: 297-311.
4. Takizawa S, Shinohara Y, Ogawa S, Ichimori K, Nakazawa H: Glutamate-related and unrelated nitric oxide production in forebrain ischemia. J Stroke Cerebrovasc Dis 1996; 6: 43-46.
5. Siesjo BK: Cell damage in the brain: a speculative synthesis. J Cereb Blood Flow Metab 1981; 1: 155-185.
6. Siesjo BK, Agardh C-D, BengtssonF: Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1989; 1: 165-211.
7. (Pubitemid 28082507) Fukuyama N, Takizawa S, Ishida H, Hoshiai K. Shinohara Y, Nakazawa H: Peroxynitrite formation in focal cerebral ischemia-reperfusion in rats occurs predominantly in the peri-infarct region. J Cereb Blood Flow Metab 1998 ; 18: 123-129.
8. (Pubitemid 30161219) Takizawa S, Fukuyama N, Hirabayashi Y, Nakazawa H, Shinohara Y: Dynamics of nitrotyrosine formation and decay in rat brain during focal ischemia-reperfusion. J Cereb Blood Flow Metab 1999 ; 19: 667-672.
9. (Pubitemid 29287519) Hirabayashi Y, Takizawa S, Fukuyama N, Nakazawa H, Shinohara Y: NMDA receptor antagonist reduces nitrotyrosine formation in caudate-putamen in rat focal cerebral ischemia-reperfusion. Neurosci Lett 2001; 299: 159-161.
10. Hirabayashi Y, Takizawa S, Fukuyama N. Nakazawa H, Shinohara Y: 7-nitro indazole attenuates nitrotyrosine formation in the early phase of cerebral ischemiareperfusion. Neurosci Lett 1999: 268: 111-113.
11. Zivin J, Mazzarella V: Tissue plasminogen activator plus glutamate antagonists improve outcome after embolic stroke. Arch Neurol 1991; 48: 1235-1240.
12. Bowes MP. Rothlein R, Fagan SC, Zinvin JA: Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995 ; 45: 815-819.
13. (Pubitemid 26148409) Meden P. Overgaard K, Pedersen H, Boysen G: Effect of early treatment with tirilazad (U74006F) combined with delayed thrombolytic therapy in rat embolic stroke. Cerebrovasc Dis 1996: 6: 141-148.
14. (Pubitemid 32947376) Lyden P, Jacoby M, Schim J, Albers G, Maazzeo P. Ashwood: The clomethiazole acute stroke study in tissue type plasminogen activator-treated stroke (CLASS-T). Neurology 2001; 57: 1199-1205.
15. (Pubitemid 32973959) Grotta J: Combination therapy stroke trial: Recombinant tissue-type plasminogen activator with/without Lubeluzole. Cerebrovasc Dis 2001; 12: 258-263.